https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-november-6-2026/ 2026-11-06T21:45:20Z Pharminent en GLP-1 Competitive Market Digest • Weekly • November 6, 2026 2026-11-06T21:45:20Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-november-6-2026/ 2026-11-06T18:43:23Z Pharminent en Strategic News Watch • November 6, 2026 2026-11-06T18:43:23Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-november-5-2026/ 2026-11-06T12:54:36Z Pharminent en Rare Disease & Gene Therapy Digest • November 5, 2026 2026-11-06T12:54:36Z Blog https://pharminent.com/fda-grants-accelerated-approval-to-rybrevant-faspro-in-head-and-neck-cancer/ 2026-11-06T12:46:09Z Pharminent en FDA grants accelerated approval to Rybrevant Faspro in head and neck cancer 2026-11-06T12:46:09Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-november-5-2026/ 2026-11-05T21:25:10Z Pharminent en Strategic News Watch • November 5, 2026 2026-11-05T21:25:10Z Blog https://pharminent.com/cvs-health-to-split-into-two-separate-companies/ 2026-11-05T12:58:27Z Pharminent en Boehringer Ingelheim strikes $7B alliance with Sino Biopharma 2026-11-05T12:45:38Z Blog